Monday, April 11, 2011

Seniors Group Asks Medicare Part-D Plans To Provide Affordable Gout Medication For Patients


Main Category: Medicare / Medicaid / SCHIP
Also Included In: Gout
Article Date: 25 Feb 2011 - 2:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
5 starsnot yet rated
As part of the 60 Plus Association's "Keeping Seniors Safe" project, the organization's chairman, Jim Martin, recently sent letters to the CEOs of five Part-D Medicare plans, urging them to provide accessible colchicine-based medications to gout patients after untested and potentially harmful options were removed from the marketplace as part of an important Food and Drug Administration (FDA) safety-initiative.

"In light of the FDA's removal of unapproved colchicine from the market, [these outlying companies] must follow the lead of other Part-D insurers around the country and reclassify COLCRYS as a tier-1 or 2 drug to ensure seniors have access to their vital gout medications" Martin wrote to the CEOs of the companies. "It is unjust to force patients to suffer through often excruciatingly-painful acute gout flare-ups despite the fact that they were promised affordable coverage for their medications."

The FDA's "Unapproved Drugs Initiative" calls for the removal of unapproved drugs from the market when approved versions exist. The agency recently acted on this initiative by removing untested colchicine products from the market.

"The FDA did what was best for patients by removing untested colchicine products from the market," wrote Martin. "We hope your company will also act in the best interest of patients and immediately work to ensure that seniors enrolled in your Part-D plan have access to the colchicine products they were promised-and sorely need."

In addition to the CEOs of offending insurance companies, copies of Martin's letter were sent to Secretary of Health and Human Services Kathleen Sebelius, HHS Deputy Secretary William Corr, CMS Administrator Donald Berwick, Senator Bill Nelson (D-FL), Representative Pete Stark (D-CA), Representative Nancy Pelosi (D-CA), Representative Henry Waxman (D-CA), Senator Chuck Schumer (D-NY), Senator Sherrod Brown (D-OH), Senator Robert Menendez (D-NJ), Senator John Cornyn (R-TX), and Representative Allyson Schwartz (D-NY).

Source:
60 Plus Association

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

posted by Gregg on 25 Feb 2011 at 9:36 am

Where the article is mistaken is in saying that the former versions of Colchicine were "potentially harmful". There is nothing different chemically about Colcrys, it merely has different labeling. For the privilege of getting this new "special" label on the package, the FDA says you must pay one-hundred and fifty dollars (or more) a month, instead of the previous twenty dollars or so.

| post followup | alert a moderator |


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Innovative Technique Gives Vision Researchers Insight Into How People Recognize Faces


Main Category: Eye Health / Blindness
Also Included In: Neurology / Neuroscience;  Biology / Biochemistry
Article Date: 17 Mar 2011 - 3:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
It is no surprise to scientists that the largest social network on the web is called Facebook. Identifying people by their face is fundamental to our social interactions, one of the primary reasons vision researchers are trying to find out how our brain processes facial identity.

In a study recently published in the Journal of Vision, scientists used an original approach a method that "shakes" the brain gently and repeatedly by making an image appear and disappear at a constant rate to evaluate its sensitivity to perceiving facial identity. The technique is called steady-state visual evoked potential (SSVEP).

"If we measure global human brain activity when one face is viewed, it cannot be differentiated from brain activity when another face is viewed," said author Bruno Rossion, PhD, a researcher at the Institute of Psychology and Institute of Neuroscience, Université Catholique de Louvain, Belgium. "This is why we relied on a method in which brain activity is compared between repetition of the same face and the presentation of different faces in succession."

During the experiment, 12 participants were presented with a series of faces appearing at a frequency of 3.5 faces per second. The result showed the brain signal at that specific frequency only was much larger when a sequence of different faces was presented at that rate than when an identical face was repeated.

The research team was positively surprised by the resulting large size of the difference between the two conditions, obtained only after one minute and a half of testing, and was equally astonished that the difference in conditions did not exist when the faces were inverted. The study also confirmed that the region for face perception lies primarily in the posterior part of the brain's right hemisphere.

The ability to recognize a face is a common problem in cases of sudden onset of posterior brain damage, neurodegenerative disorders like Alzheimer disease and other forms of dementia and social disorders such as autism. Rossion points out that an advantage of using this highly sensitive SSVEP methods is that it can be used and compared objectively in different human populations adults, infants, children, neurological patients, people with long-life face recognition impairments or autism - without requiring complex instructions and a long testing duration.

"Face recognition involves the most complex aspects of perception and memory and, for this reason, understanding how it works has large-scale implication," Rossion adds. "Ultimately, through a better understanding of this function, we will make tremendous progress in our understanding of how the brain works in general, develop tools to detect its dysfunction and hopefully help remedy it."

Source: Association for Research in Vision and Ophthalmology (ARVO)

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Sunday, April 10, 2011

American Optometric Association Awards ACUVUE(R) ADVANCE(R) Plus Brand Contact Lenses With Seal Of Acceptance For UV Absorbing Contact Lenses


Main Category: Eye Health / Blindness
Article Date: 18 Mar 2011 - 2:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
ACUVUE® ADVANCE® Plus Brand Contact Lenses became the sixth contact lens in the ACUVUE® Brand family of products to receive the Seal of Acceptance for Ultraviolet Absorbing Contact Lenses from the American Optometric Association's (AOA) Commission on Ophthalmic Standards.

In awarding the Seal of Acceptance, AOA's Commission on Ophthalmic Standards, which provides independent evaluation of ophthalmic related products, determined that ACUVUE® ADVANCE® Plus Brand meets AOA specifications for ultraviolet absorbing contact lenses. These specifications are in accordance with published standards of the American National Standards Institute (ANSI) and International Standards Organization (ISO).

"For those who need vision correction, a significant measure of UV protection can be achieved with a combination of UV-absorbing sunglasses, a wide-brimmed hat, and UV-blocking contact lenses," says Karl M. Citek, OD, Ph.D., Chair of the Commission on Ophthalmic Standards.

"Not all contact lens lines offer UV protection, and, of those that do, not all provide similar absorption levels," explains Sheila Hickson-Curran, Director, Medical Affairs, VISTAKON®, Division of Johnson & Johnson Vision Care, Inc.

All ACUVUE® Brand Contact Lenses offer effective UV-blocking, and among contact lens brands, only ACUVUE® ADVANCE® Plus, 1•DAY ACUVUE® TRUEYETM, ACUVUE® OASYS® with HYDRACLEAR® PLUS, ACUVUE® OASYS®for ASTIGMATISM, ACUVUE® ADVANCE® with HYDRACLEAR®, and ACUVUE® ADVANCE® for ASTIGMATISM Brand Contact Lenses carry the AOA's Seal of Acceptance for Ultraviolet Absorbing Contact Lenses. These contact lenses offer the highest level of UV-blocking available, blocking more than 90 percent of UVA rays and 99 percent of UVB rays that reach the lens.† * On average, contact lenses without UV-blocking capability allow 90% of UVA radiation and 70% of UVB radiation to pass through the lenses to your eyes.

"Although UV-blocking contact lenses provide important added protection for patients, they should not be viewed as a stand-alone solution," notes Dr. Citek. "Contact lenses should always be worn in conjunction with high-quality UV-blocking sunglasses and a wide-brimmed hat for maximum UV protection for the eyes."

Important information for contact lens wearers: ACUVUE® Brand Contact Lenses are available by prescription only for vision correction. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and the lens care instructions provided by your eye doctor. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, contact your eye doctor immediately.

† Helps protect against transmission of harmful UV radiation to the cornea and into the eye.

* WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. You should continue to use UV-absorbing eyewear as directed. NOTE: Long term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-Blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-Blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care practitioner for more information.

Source:
Johnson & Johnson Services, Inc.

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

New Approaches To Dementia And Sight Loss - Report Of First National Conference Released Today, UK

Translate Request has too much data
Parameter name: request

Main Category: Alzheimer's / Dementia
Also Included In: Eye Health / Blindness
Article Date: 16 Mar 2011 - 1:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
5 starsnot yet rated
Key messages for professionals, policy makers, commissioners and carers are highlighted in a report released today (1) of the First National Conference on Dementia and Sight Loss.

The report, by the Dementia and Sight Loss Interest Group (DaSLIG), a coalition of leading charities, (2) summarises the presentations and discussions delivered at the recent National Conference in London. Organised by DaSLIG and sponsored by ARUP, the conference brought together over 70 delegates - sight loss and dementia specialists as well as representatives from bodies including the Department of Health, NHS and Social Care Institute for Excellence.

"This conference was a milestone in the bid to improve the lives of people living with both dementia and sight loss," said Sarah Buchanan, Research and Development Manager, Thomas Pocklington Trust. "It was the first major debate on this issue and it delivered crucial information and practical solutions for improving care. The report should be essential reading for all those involved in the care and support of people with dementia."

Of the estimated 750,000 people in the UK living with dementia, at least 100,000 will also have serious sight loss yet, in 2010, a review of existing dementia policy, practice and literature, summarised for the conference by Dr. Declan McKeefry (3), (Bradford University School of Optometry and Vision Science), concluded that all three displayed a "fundamental lack of sensitivity to sight loss."

He highlighted three main types of sight loss associated with dementia. A specific eye condition might occur at the same time as dementia; some forms of dementia affect vision, including perception of colour, depth and detail; and, thirdly, normal ageing of the eyes plays an important role since most people with dementia are over the age of 75.

Despite this, his research showed that few people with dementia appear to have access to regular eye tests.

"Ocular health screening is important in people with dementia, yet there's a reticence to refer them," he said.

At the conference, Fazilet Hadi, Group Director Inclusive Society, RNIB, spelled out the realities of living with dementia and sight loss. The emotional impact on people's identity, confidence and self worth are underestimated and a lot of people are not getting the services they need.

"Having both dementia and sight loss is qualitatively different than having one or the other. But when dementia is the main condition sight loss can be forgotten," she said.

Dr. Graham Stokes, Director of Dementia Care for BUPA, had seen many cases of dementia related sight loss. He called it "not seeing with true knowledge". In a moving account he described a man whose dementia and sight loss led to terror at his own reflection. Too often carers were insensitive to this kind of fear and alarm. He classified this as "malign care" and urged carers to "move beyond quality of care to quality of life." He listed practical examples for improving care in care homes. For example: how to deliver "high intensity engagement" to people with dementia. Even 90 seconds of interaction can give long-lasting feelings of wellbeing:

"The positive feeling exists far longer than the memory of the interaction," he said. "Carers, you do have time to give people one-to-one attention."

The National Dementia Strategy was setting a pathway for change, said Professor Sube Banerjee, leading specialist in dementia and co-leader on development of the national strategy.

"At the moment we spend a lot of money - late - on things that aren't of good quality," he said.

He cited "waiting too long and not focussing on prevention" as major failings. Late diagnosis was resulting in "harm, crisis and cost," he said, with only 30% of people with dementia ever diagnosed. Now, early diagnosis and intervention "including the diagnosis of important co-morbidities such as sight loss" is a key aim of the National Dementia Strategy.

The huge cost of dementia care - £17 billion a year in the UK - would be a powerful driver of change:

"Doing dementia care well will cost less than doing it badly. Doing it well becomes the solution rather than the problem."

Andrew Chidgey, Head of Policy and Public Affairs at the Alzheimer's Society, said the scene was set for achieving change.

"There is a willingness of people to talk more freely about members of their family who have dementia. With this increased awareness and willingness to act there is an opportunity now to do far more on dementia linked to sight loss."

Other speakers highlighted in the report include:

Professor David Croisdale-Appleby OBE (Skills for Care) on how qualifications available from January 2011 will improve the knowledge, understanding and status of social care staff.

Penny Redwood (freelance trainer) on how to recognise concurrent sight loss and dementia.

Pam Turpin, (ARUP) giving a room-by-room account of making a home dementia and sight loss friendly.

Notes:

1. Dementia and Sight Loss Conference - Summary of Conference available here.

2. The Dementia and Sight Loss Interest Group (DaSLIG) of VISION 2020 UK is led by Alzheimer's Society, Macular Disease Society, ARUP, Royal National Institute of Blind People (RNIB) and Thomas Pocklington Trust. This special interest group leads work to raise awareness of concurrent dementia and sight loss.

3. Research papers available here.
The key papers presented by Professor Sube Banerjee and Dr. Declan McKeefry are:
"The experiences and needs of people with dementia and serious visual impairment: a qualitative study" by Vanessa Lawrence, Joanna Murray, Dr. Dominic ffytche and Professor Sube Banerjee, King's College London.
"The development of professional guidelines for the eye examination of people with dementia" D. McKeefry. University of Bradford Schools of Optometry and Vision Science. The findings of this study are included in Thomas Pocklington Trust Research Discussion Paper number 8 - "Improving the provision of vision and eye health care to people with dementia"

4. The research led by Professor Sube Banerjee at Kings College, London, and supported by Thomas Pocklington Trust, shows that in dementia a person's orientation, recognition, recall and judgement are all exacerbated by sight loss, making the impact of dementia worse. Sight loss can increase feelings of confusion, isolation and fear and this, in turn, may trigger aggression. At the same time, a person's ability to cope with sight loss is reduced by dementia. Responding to people's sight loss, suggests the research, could reduce both the distress of dementia and the likelihood of disruptive behaviour.

Source:
Thomas Pocklington Trust

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

posted by Jim on 26 Mar 2011 at 12:11 am

My wife Patricia was diagnosed with alzheimers in 2000 at the age of 57. Her eyes are perfect, but the brain cells for seeing have died. She had trouble seeing in 1998, and is now blind. It is advisable to be checked out for alz if one is having to use spectacles for the first time at 35 years and over. Alzheimers may be the cause.

| post followup | alert a moderator |


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

InSite Vision Announces Positive Phase 1/2 Results For ISV-303 For The Reduction Of Pain And Inflammation After Cataract Surgery

Error in deserializing body of reply message for operation 'Translate'. The maximum string content length quota (8192) has been exceeded while reading XML data. This quota may be increased by changing the MaxStringContentLength property on the XmlDictionaryReaderQuotas object used when creating the XML reader. Line 1, position 8758.

Main Category: Eye Health / Blindness
Also Included In: Pain / Anesthetics
Article Date: 23 Mar 2011 - 9:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
InSite Vision Incorporated (OTCBB:INSV) announced top-line results from its recently completed Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. This randomized four-arm study compared once- and twice-daily doses of ISV-303 versus Xibrom™ and DuraSite® (vehicle), each administered twice-daily. ISV-303 combines a lower dose (0.075%) of the non-steroidal anti-inflammatory (NSAID) bromfenac (BROMDAY™/Xibrom (bromfenac ophthalmic solution) 0.09%, marketed by ISTA Pharmaceuticals) with InSite Vision's proprietary DuraSite drug delivery technology.

The Phase 1/2 clinical trial enrolled 169 patients undergoing cataract surgery. The primary endpoint of the study was the absence of cells in the anterior chamber of the eye at day 15 post surgery. Once-daily ISV-303 achieved statistically significant superiority compared to vehicle (53.3% vs. 19.0%, p=0.0016) for the primary endpoint. Further, secondary endpoints such as reduction of flare, pain and discomfort as a result of inflammation, achieved statistically significant superiority at days 8, 15 and 29 as compared with vehicle. While once-daily ISV-303 achieved a numerically superior difference in the primary endpoint versus twice-daily Xibrom (53.3% vs. 42.2%), the results did not reach statistical significance given the relatively small size of the trial. ISV-303, Xibrom and vehicle were all generally well tolerated and there were no safety concerns or serious adverse events related to any of the agents. InSite Vision intends to present a final analysis of the ISV-303 Phase 1/2 clinical trial in conjunction with a future scientific meeting.

The exploratory Phase 1/2 study was not designed to achieve statistically significant difference between the arms. Nevertheless, the results of this relatively small study comfortably demonstrate the clear efficacy and safety of once-daily ISV-303 over DuraSite in terms of a regulatory pathway, and the promise of a commercially superior once-daily NSAID for post-surgical use in the marketplace. Following final analysis, the Company plans to initiate discussions with the U.S. Food and Drug Administration (FDA) on the design of the pivotal Phase 3 program for once-daily ISV-303. The Company also plans to conduct a Phase 2 pharmacokinetic study of once-daily ISV-303 against ISTA Pharmaceutical's currently marketed once-daily NSAID, BROMDAY.

"It is a delightfully rare situation to experience such stunningly statistically significant results in an exploratory Phase 1/2 study," said Timothy Ruane, Chief Executive Officer of InSite Vision. "With the efficacy and safety profile established in this study, and potential patent protection extending to 2029, we believe once-daily ISV-303 is very well positioned to compete in the growing $300 million ophthalmic NSAID market in the United States. Importantly, the results of this study further transform InSite Vision into a late-stage company with three Phase 3 candidates that we intend to move toward approval."

InSite Vision is advancing another product candidate that utilizes a low-concentration of bromfenac enabled by DuraSite. ISV-101, a lower dose of bromfenac in DuraSite, is being developed for the treatment of dry eye disease. On January 11, 2011, InSite Vision announced it had filed an Investigational New Drug (IND) application for ISV-101 with the FDA. The Company is now positioned to initiate a dose-ranging Phase 1/2 clinical trial in 2011 to evaluate the safety and efficacy of ISV-101 when administered to patients suffering from dry eye disease. Patent protection for this drug candidate is also expected to extend into 2029. Preclinical data on the safety of ISV-303 and ISV-101 (bromfenac formulated in DuraSite) on ocular tissues have been accepted for presentation at the 2011 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 1 - 5, 2011 in Fort Lauderdale, Florida.

Cataract surgery is the most frequently performed ocular surgery in the United States with more than three million procedures annually. Following surgery, anti-inflammatory eye drops are typically prescribed to reduce pain and inflammation and to enhance healing.

Dry eye disease occurs when the surface of the eye becomes compromised for various reasons, frequently involving tear-film changes. While causes of dry eye may vary, it is frequently associated with inflammation of the surface of the eye, the lacrimal gland, and/or the conjunctiva. A potentially chronic condition that can occur at any age, dry eye disease is most prevalent among the elderly. It is estimated to affect at least twenty-five million people in the U.S. alone.

About DuraSite®

InSite's DuraSite sustained delivery technology is a patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and can be customized for delivering a wide variety of potential drug candidates. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1% and Besivance™ (besifloxacin ophthalmic suspension) 0.6%. InSite vision is also applying DuraSite to multiple other clinical- and preclinical-stage product candidates to create a portfolio of novel ophthalmic products.

Source:
InSite Vision

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

New CNIB Survey Finds Many Canadians Less Than Well-Informed About Family History Of Glaucoma


Main Category: Eye Health / Blindness
Article Date: 21 Mar 2011 - 1:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
According to a new CNIB survey released this week for World Glaucoma Week (March 7-13), few Canadians are as informed as they need to be about their family history of glaucoma, a serious and incurable eye condition that affects 250,000 Canadians.

Despite the fact that glaucoma tends to run in families, the survey found that almost half of Canadians (47 per cent) do not feel well-informed about their family history of the disease. In fact, only one-third of Canadians (33 per cent) have spoken to their immediate families to learn whether glaucoma could be a hereditary concern.

But astonishingly, among the group that reported having had that conversation, almost half (47 per cent) learned that glaucoma was in the family, indicating they could be at an elevated risk.

"People forget that learning about your family history of glaucoma is an important step to protecting your eyesight. Family history, particularly having a parent or sibling with the disease, is considered one of the primary risk factors of glaucoma," said Dr. Keith Gordon, Vice-President of Research and Service Quality, CNIB.

The survey also revealed that most Canadians (71 per cent) are unaware that you could have glaucoma, but still be able to see perfectly well.

Eye Remember

To educate Canadians about the importance of detecting glaucoma early, CNIB has launched its third annual awareness campaign and photo contest called "Eye Remember." From March 8 to May 18, Canadians can visit www.eyeremember.ca to get the facts on glaucoma and upload a photograph that represents a cherished memory from their past - whether it's a summer with family at the cottage, a shot from your honeymoon, or an old black and white picture from grandma's albums - along with a brief description of why it is close to their heart and reminds them to be proactive about their vision health.

All uploaded photos will be entered for a chance to win a once-in-a-lifetime trip for two to one of four popular Canadian destinations, including Banff (Alberta), Quebec City (Quebec), Niagara Falls (Ontario) and the Okanagan Valley (British Columbia).

Glaucoma: The "silent thief"

Caused by damage to the optic nerve, glaucoma usually progresses slowly and painlessly; therefore it's possible to have glaucoma without noticing any symptoms or major changes to your eyesight. In fact, 125,000 Canadians are living with glaucoma today and don't know it.

"Because glaucoma has no symptoms, it can only be picked up by regular eye examinations with an eye doctor," said Dr. Neeru Gupta, Professor, Dorothy Pitts Chair of Ophthalmology and Vision Sciences, and Director of the Glaucoma Unit at St. Michael's Hospital, University of Toronto. "If someone in your family has glaucoma, you are at a much higher risk for the disease. Get your eye pressure and optic nerves checked for glaucoma. Early treatment is a powerful way to prevent vision loss."

In addition to family history, risk factors for glaucoma include having elevated eye pressure, being over the age of 40, being of African, Asian or Inuit descent and having myopia.

Over time, glaucoma may cause loss of peripheral (side) vision, followed by "tunnel" vision or complete vision loss. There is no cure for glaucoma and, once you begin to lose your vision, it can't be restored. Fortunately, vision loss from glaucoma can be controlled if detected early.

About the survey

This survey was conducted as part of CNIB's Eye Remember campaign in order to determine how much Canadians know about glaucoma and its risk factors. A random sample of 1,003 Canadians aged 18 and older answered an online survey. Survey results from a sample of Canadians of this size can be considered accurate to +/- 3.1 per cent, 19 times out of 20. The survey was undertaken by CNIB, with data collection by Ipsos Public Affairs. Eye Remember is supported by an unrestricted educational grant from Pfizer Canada Inc.

Source:
CNIB

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here